Dyadic International, Inc. Appoints Arindam Bose to Board of Directors
August 16, 2016 at 08:42 pm IST
Share
Dyadic International, Inc. announced the appointment of Arindam Bose, Ph.D., to its Board of Directors, effective August 15, 2016. Dr. Bose recently retired from Pfizer Research & Development after serving for 34 years, most recently in senior leadership roles in process development and manufacturing of biologics.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.